RxDoctor Payments Data

Bhadresh Bhakta, MD

Interventional Pain Medicine · Tulsa, OKNPI 1184606550

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 96.7% of the total across 81 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by Scilex Pharmaceuticals Inc. at 31.1% of the total. Reporting peaked in 2019 at $280 and has fallen 58.2% since, to $117 in 2025. That places this record below the midpoint for interventional pain medicine clinicians in OK, where the typical reported total is $5,016.

$1,071in general payments, 2019–2025

Across 81 payments — averaging $13.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Scilex Pharmaceuticals Inc.$333
  • GRT US Holding, Inc.$152
  • Collegium Pharmaceutical, Inc.$101
  • Lilly USA, LLC$76
  • Pfizer$73
  • Averitas Pharma Inc.$63
  • plus $271 from 9 others

What the payments were for

  • Food & beverage$1,03697%
  • Education$353%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,071 in reported general payments places this provider in the 25th percentile of 27 interventional pain medicine providers in Oklahoma.

See all interventional pain medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$90,704
Medicare patients
63
Services billed
11,764

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UbrelvyUbrogepant12$40,417
BelbucaBuprenorphine Hcl38$28,880
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen408$7,415
Buprenorphine18$7,192
Oxycodone Hcl241$3,166
Morphine Sulfate115$3,138
Morphine Sulfate ErMorphine Sulfate141$3,075
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen112$2,904
Butalbital-Acetaminophen-CaffeButalb/Acetaminophen/Caffeine25$1,017
Tizanidine Hcl112$978
Gabapentin53$905
Tramadol Hcl ErTramadol Hcl13$854
Naloxone Hcl12$750
Tramadol Hcl54$639
Topiramate46$586

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy$33$40,41712 claims
Collegium Pharmaceutical, Inc.Belbuca$101$28,88038 claims
Hikma Pharmaceuticals USABuprenorphine, Morphine Sulfate$35$10,331133 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 27 interventional pain medicine providers in Oklahoma.

Other interventional pain medicine in Tulsa

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →